Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Near term planning for the globalisation of Penthrox

May 8, 2015Cathy WilsonNews

8 May 2015

ASX ANNOUNCEMENT

Near term planning for the globalisation of Penthrox

The approval of Penthrox for use in the United Kingdom, France, Belgium and Ireland validates our Regulatory Dossier and the clinical and safety data we have obtained for Penthrox.? It proves Penthrox is a ?world class? product which regulatory authorities around the world can approve for sale.

With the successful closure of the Decentralised Procedure (DP) and ultimate approval in Europe, MVP plans to aggressively expand the number of countries which can sell Penthrox:

For more information click on the link:?ASX Announcement – Near term planning for the globalisation of Penthrox

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Appointment of Non-Executive Director – Mary Sontrop

    5 March 2021 ASX ANNOUNCE...

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.